<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099109</url>
  </required_header>
  <id_info>
    <org_study_id>16526</org_study_id>
    <secondary_id>I9A-MC-JLDA</secondary_id>
    <secondary_id>2016-003195-42</secondary_id>
    <nct_id>NCT03099109</nct_id>
  </id_info>
  <brief_title>A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors</brief_title>
  <official_title>A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an&#xD;
      anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody&#xD;
      administered alone or in combination with LY3300054, an anti-programmed death ligand 1&#xD;
      (PD-L1) antibody, in participants with advanced relapsed/refractory solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 12, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">December 10, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with DLTs</measure>
    <time_frame>Baseline through Cycle 1 (28 Day Cycle)</time_frame>
    <description>Dose Limiting Toxicity (DLT) is defined as an adverse event (AE) that meets protocol defined DLT criteria during cycle 1 and is at least possibly related to study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of LY3321367</measure>
    <time_frame>Cycle 1 Day 1 through Follow-Up (Estimated up to 6 Months)</time_frame>
    <description>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3321367</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of LY3321367 in Combination with LY3300054</measure>
    <time_frame>Cycle 1 Day 1 through Follow-Up (Estimated up to 6 Months)</time_frame>
    <description>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3321367 in Combination with LY3300054</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR: Percentage of Participants With a CR or PR</measure>
    <time_frame>Baseline to Measured Progressive Disease (Estimated up to 6 Months)</time_frame>
    <description>Objective Response Rate (ORR) is the percentage of participants with confirmed best overall tumor response of Complete Response (CR) or Partial Response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated Up to 12 Months)</time_frame>
    <description>Progression Free Survival (PFS) is defined as the date of the first dose to the first date of objectively determined progressive disease or death from any cause, whichever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>Date of CR or PR to Date of Objective Progression or Death Due to Any Cause (Estimated up to 12 Months)</time_frame>
    <description>Duration of Response (DoR) is defined as the time from the date of the first CR or PR to the first date of progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR</measure>
    <time_frame>Baseline to Date of CR or PR (Estimated up to 6 Months)</time_frame>
    <description>Time to Response (TTR) is defined as time from treatment start to first documentation of response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR: Percentage of Participants who Exhibit SD, CR or PR</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 6 Months)</time_frame>
    <description>Disease Control Rate (DCR) is the percentage of participants with stable disease (SD), confirmed PR or confirmed CR (CR+PR+SD).</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>LY3321367 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3321367 given intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3321367 + LY3300054 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3321367 and LY3300054 given IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3321367 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3321367 given IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3321367 + LY3300054 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3321367 and LY3300054 given IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Arm D LY3321367</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3321367 given IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Arm E LY3300054</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3300054 given IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Arm F LY3321367 + LY3300054</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3321367 and LY3300054 given IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3321367</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Japanese Arm D LY3321367</arm_group_label>
    <arm_group_label>Japanese Arm F LY3321367 + LY3300054</arm_group_label>
    <arm_group_label>LY3321367 + LY3300054 Dose Escalation</arm_group_label>
    <arm_group_label>LY3321367 + LY3300054 Dose Expansion</arm_group_label>
    <arm_group_label>LY3321367 Dose Escalation</arm_group_label>
    <arm_group_label>LY3321367 Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3300054</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Japanese Arm E LY3300054</arm_group_label>
    <arm_group_label>Japanese Arm F LY3321367 + LY3300054</arm_group_label>
    <arm_group_label>LY3321367 + LY3300054 Dose Escalation</arm_group_label>
    <arm_group_label>LY3321367 + LY3300054 Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For Ph1a monotherapy and combination cohorts, histologic or cytologic confirmation of&#xD;
             advanced solid tumor.&#xD;
&#xD;
          -  For Phase 1a and 1b, prior PD-1 or PD-L1 therapy or other immunotherapy is allowed, if&#xD;
             the following criteria are met:&#xD;
&#xD;
               -  Must not have experienced a toxicity that led to permanent discontinuation of&#xD;
                  prior immunotherapy.&#xD;
&#xD;
               -  Must have completely recovered or recovered to baseline prior to screening from&#xD;
                  any prior AEs occurring while receiving prior immunotherapy.&#xD;
&#xD;
          -  Must have provided tumor tissue sample, as follows:&#xD;
&#xD;
               -  For participants entering Ph1a: have submitted, if available, an archival tumor&#xD;
                  tissue sample.&#xD;
&#xD;
               -  For participants entering Ph1b: have submitted, a sample from a newly obtained&#xD;
                  core or excisional biopsy of a tumor lesion or a recent biopsy defined by 6&#xD;
                  months of study enrollment (Ph1b).&#xD;
&#xD;
          -  Must have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group&#xD;
             (ECOG) scale.&#xD;
&#xD;
          -  Must have adequate organ function.&#xD;
&#xD;
          -  Have an estimated life expectancy of 12 weeks, in judgement of the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have symptomatic or uncontrolled brain metastases, spinal cord compression, or&#xD;
             leptomeningeal disease requiring concurrent treatment, including but not limited to&#xD;
             surgery, radiation, and/or corticosteroids (participants receiving anticonvulsants are&#xD;
             eligible).&#xD;
&#xD;
          -  Have received a live vaccine within 30 days before the first dose of study treatment.&#xD;
&#xD;
          -  If female, is pregnant, breastfeeding, or planning to become pregnant.&#xD;
&#xD;
          -  Have a history or current evidence of any condition, therapy, or laboratory&#xD;
             abnormality that might interfere with the participant's participation.&#xD;
&#xD;
          -  Have moderate or severe cardiovascular disease.&#xD;
&#xD;
          -  Have a serious concomitant systemic disorder that would compromise the participant's&#xD;
             ability to adhere to the protocol, including active or chronic infection with human&#xD;
             immunodeficiency virus (HIV), active hepatitis B virus (HBV), active hepatitis C virus&#xD;
             (HCV), active autoimmune disorders, or prior documented severe autoimmune or&#xD;
             inflammatory disorders requiring immunosuppressive treatment.&#xD;
&#xD;
          -  Use of escalating or chronic supraphysiologic doses of corticosteroids or&#xD;
             immunosuppressive agents (such as, cyclosporine). [Use of topical, ophthalmic,&#xD;
             inhaled, and intranasal corticosteroids permitted].&#xD;
&#xD;
          -  Bowel obstruction, history or presence of inflammatory enteropathy or extensive&#xD;
             intestinal resection.&#xD;
&#xD;
          -  Evidence of interstitial lung disease or noninfectious pneumonitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM- 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Phys &amp; Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peggy and Charles Stephenson Oklahoma Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The START Center for Cancer Care</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277 8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-Ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz-Oncology</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Norte Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/solid-tumor/JLDA#?postal=</url>
    <description>A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors</description>
  </link>
  <verification_date>September 1, 2021</verification_date>
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TIM-3</keyword>
  <keyword>PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

